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Wireless deep brain stimulation of well-defined neuronal populations could facilitate the study 
of intact brain circuits and the treatment of neurological disorders. Here we demonstrate 
minimally-invasive and remote neural excitation through the activation of the heat-sensitive 
capsaicin receptor TRPV1 by magnetic nanoparticles. When exposed to alternating magnetic 
fields, the nanoparticles dissipate heat generated by hysteresis, triggering widespread and 
reversible firing of TRPV1
+ 
neurons. Wireless magnetothermal stimulation in the ventral 
tegmental area of mice evoked excitation in subpopulations of neurons in the targeted brain 
region and in structures receiving excitatory projections. The nanoparticles persisted in the 





Stimulation of deep brain structures affected by treatment-resistant psychiatric and neurological 
disorders can ameliorate associated symptoms but is currently only achieved by permanently 
implanted electrodes (1). Second-generation neuromodulation technologies rely on acoustic (2), 
electromagnetic induction (3), or optical (4) signals. These fields are largely absorbed and 
scattered by tissue and similarly require a conduit for deep brain stimulation. In contrast, low-
radiofrequency alternating magnetic fields (100 kHz – 1 MHz) can penetrate into the body 
without significant attenuation and thus enable signal delivery into deep brain regions (5). 
Alternating magnetic fields can be converted into biological stimuli by magnetic 
nanoparticles (MNPs) that dissipate heat via hysteretic power loss (6). While MNP heating 
has been investigated as a cell destructive therapy in magnetic hyperthermia for fifty years (7), 
this effect has  onl y recent l y been  exploited for control o f  cell membrane depolarization 
and gene expression in engineered xenografts and invertebrates (8, 9). Magnetothermal control 
of neural activity in vivo in a mammalian system remains to be demonstrated. 
To achieve reversible neuronal activation with alternating magnetic fields, we developed 
an intracellular calcium control scheme by sensitizing cells to heat generated from MNPs (Fig. 
1A). Earlier experiments relied on synthetic transgenes to target MNPs to the cell membrane 
and required 10s to 1000s of seconds to observe increased calcium ion (Ca
2+
) influx, which 
exceeded temporal dynamics of neuronal firing by orders of magnitude. Recent studies suggest 
that MNP functionalization with proteins induces cell internalization and the formation of 
protein coronas that may reduce the effectiveness of targeting and heat dissipation in vivo 
(10, 11). We reasoned that un-targeted Fe3O4 MNPs optimized for efficient heat dissipation at 
clinically relevant alternating magnetic field conditions can (i) reduce the latency period for 
neural excitation, (ii) eliminate exogenous targeting transgenes, and (iii) have chronic utility in 
vivo because MNPs exhibit minimal cytotoxicity and remain intact several months after injection 
(12, 13). Spherical Fe3O4 MNPs 22 nm in diameter possess some of the highest heating rates 
per gram, or specific loss power, measured for a synthetic material at a therapeutically relevant 
frequency ƒ=500 kHz and field amplitude Ho=15 kA/m (14). We prepared these monodisperse 
MNPs via the thermal decomposition of an environmentally benign iron-oleate precursor (15), 
and dispersed them in water through high-temperature ligand exchange with poly(acrylic acid) 
(Fig. 1B) (14). Grafting poly(ethylene glycol) chains onto poly(acrylic acid) coated MNPs 
resulted in their steric dispersion, which improved colloidal stability (Fig. 1C, D) and 
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biocompatibility, as indicated by the increased viability of human embryonic kidney 
(HEK293FT) cells over prolonged exposure (Fig. S1) (16). These MNPs exhibited specific loss 
power of 660 W/g ± 50, which is 6-fold higher than hyperthermia agents currently used in 
clinical settings (Fig. S2). Magnetic fields were generated by a resonant coil custom-designed for 
fluorescence imaging during stimulation (Fig. S3A-E). Although TRPV1 is naturally expressed 
across the mammalian nervous system (17), we designed a transgene to establish sustained and 
uniform levels of TRPV1 expression for magnetothermal membrane depolarization across 
different cell lines (18). The TRPV1 transgene was placed under the excitatory neuronal 
promoter calmodulin kinase II α-subunit along with mCherry separated from TRPV1 by the 
post-transcriptional cleavage linker p2A (CamKIIα::TRPV1-p2A-mCherry) (19) and packed into 
the lentiviral vector to enable long-term in vitro and in vivo neural transfection (20). Cells were 
additionally transfected with the adeno-associated virus serotype 9 (AAV9) carrying GCaMP6s 
under the neuronal promoter human synapsin (hSyn::GCaMP6s) for measurement of 
intracellular Ca
2+
 changes as a proxy for membrane depolarization (21). Functionality of the 
two genes was confirmed by observing increased fluorescence intensity in response to capsaicin, 
a TRPV1 agonist, and temperature increase above 43 °C in non-excitable HEK293FT cells (Fig. 
S4A-C). 
We first demonstrated magnetothermal control of intracellular Ca
2+
 influx in 
HEK293FT cells. Fluorescence intensity maps indicated that only cells expressing TRPV1 
(TRPV1
+
) responded to the field stimulus (ƒ=500kHz, Ho=15 kA/m) when incubated in MNP 
solutions (2 mg/mL), while cells not expressing TRPV1 (TRPV1
–





cells without field stimulus did not exhibit significant changes in intracellular Ca
2+ 
concentration (Fig. 1E). Field-induced temperature increase in excess of 43 °C in MNP 
solutions triggered GCaMP6s fluorescence increase ΔF/F0 > 50% in 36.1% ± 4.3 (mean ± 
std) of TRPV1
+ 
cells, while only 1.7% ± 1.6 (mean ± std) of TRPV1
– 
cells exhibited a similar 
response (Fig. 1F and Fig. S5A-D). 
Magnetothermal membrane depolarization was sufficient to evoke trains of action 
potentials in primary hippocampal neurons expressing TRPV1 when exposed to 10 s field 
pulses at 60 s intervals. Viral transfection with AAV9-hSyn::GCaMP6s, which allows for 
fluorescence detection of single action potential events (21), and Lenti-CamKIIα::TRPV1-p2A-
mCherry (TRPV1
+
) or Lenti-CamKIIα::mCherry (TRPV1–) yielded a co-expression efficiency of 





exhibited synchronized firing within 5 s following stimulus, while only sporadic activity was 
observed in TRPV1
– 
neurons (Fig. 2B-H). This implies that the temperature increase (Fig. 2D) 
in MNP solutions exposed to alternating magnetic field was sufficient to trigger TRPV1 (Fig. 
2H), while avoiding non-specific thermal effects such as changes in membrane capacitance 
(Fig. 2F) (22). In the absence of MNPs, magnetic field did not induce appreciable solution 





(Fig. 2B, E, G). We recorded neural activity from GCaMP6s temporal fluorescence traces 
(Fig. S 6A-D, Movie S1) (23). Waves of Ca
2+
 spikes were repeatedly induced by field pulses 
only in TRPV1
+ 
neurons in the presence of MNPs (Fig. 2I-P). The observed 5 s latency between 
the field application and the onset of neural activity is 5-fold faster than previously described (8). 
We next tested whether alternating magnetic field could activate a subpopulation of 
neurons in deep brain tissue in mice. Finite element modeling corroborated with temperature 
recordings in brain phantoms was used to predict local temperature changes in response to field 
stimulus (Fig. S7). Injections (2.5 µL) of MNP solution (100 mg/mL) delivered temperature 
gradients sufficient to reach the TRPV1 activation threshold within 5 s and cool back to 37 °C 
over 60 s cycles (Fig. S7B-F), thus avoiding prolonged exposure to noxious heat (Fig. S7G) 
(24). 
With low endogenous expression of TRPV1 (25) and well-characterized projections (26), 
the ventral tegmental area (VTA) was an attractive deep brain target for initial demonstration of 
magnetothermal stimulation. Furthermore, phasic excitation in the VTA has therapeutic 
implications in the treatment of major depression (27). We sensitized excitatory neurons in the 
VTA to heat by lentiviral delivery of TRPV1, which was followed by MNP injection into the 
same region four weeks later (Fig. 3A, B, S8A). The anesthetized mice were exposed to the 
magnetic field conditions described above (Fig. S8B, C). Neuronal excitation was quantified by 
the extent of activity-dependent expression of the immediate early gene c-fos within a 250 
µm vicinity of the MNP injection (Fig. 3C-F) (28). Neural activity was only triggered by 
magnetic field in the VTA of mice transfected with TRPV1 in the presence of MNPs, resulting in 
a significantly higher proportion of c-fos positive (c-fos
+
) cells as revealed by a two-way 
ANOVA with a Bonferroni post-hoc test (F1,13=47.5, P < 0.0001, Fig. 3G). Control subjects 
testing whether the MNP injection, heat dissipation with field stimulus, or TRPV1 expression 
alone can result in neural stimulation showed no significant c-fos expression (Fig. 3C-E, G). 
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Furthermore, the spatial extent of neuronal activation was largely collocated with TRPV1 
expression in the VTA (Fig. 3H, I). 
We next investigated whether neurons in the VTA can be activated 1 month after MNP 
injection to explore its chronic utility (Fig. 3J-O). We again observed increased c-fos expression 
in the VTA only in mice transfected with TRPV1 in the presence of MNPs and exposed to the 
magnetic field protocol described above (Fig.  3J, M “ON”; Student’s t-test, P < 0.02). In 
these mice, we also found evidence of field-evoked upregulation of c-fos in the medial 
prefrontal cortex (mPFC, Fig. 3K, N “ON”; Student’s t-test, P < 0.02) and nucleus accumbens 
(NAc, Fig. 3L, O “ON”; Student’s t-test, P < 0.002), which are known to receive excitatory 
inputs from VTA neurons (26, 29). In the absence of stimulation, neurons in the VTA near the 
MNP injection site and the neurons in the mPFC and NAc did not exhibit increased c-fos 
expression (Fig. 3J-O “OFF”). 
We compared the biocompatibility of the MNP injection to a similarly sized stainless 
steel implant (Fig. S9). The interface between the MNP injection and the tissue exhibited 
significantly lower glial activation and macrophage accumulation, and higher proportion of 
neurons as compared to the steel implant 1 week and 1 month after surgery (Fig. S9A-F). The 
improved tissue compatibility can likely be attributed to the mechanically pliable nature of the 
MNP injection and sequestration via endocytosis (12, 13). No difference in neuronal or glial 
density was observed between brain tissue of stimulated and unstimulated mice, suggesting that 
the rapidly dissipated magnetothermal cycles cause minimal thermal damage to the surrounding 
tissue (Fig. S9G). 
In this report, we demonstrated widespread and repeatable control of cellular signaling in 
non-excitable and electroactive cells using wireless magnetothermal stimulation in vitro and in 
vivo. Finer control over stimulation intensity to facilitate applications of this approach to 
problems in systems neuroscience can be achieved by further reducing the latency between field 
onset and evoked neural firing by developing MNPs with high specific loss powers (30) and by 
introducing heat-sensitive ion channels with lower thermal thresholds (31). Mechanosensitive 
potassium and chloride channels may serve as potential mediators of magnetothermal inhibition 
(32). While demonstrated for chronic stimulation of targeted neural circuits, this magnetothermal 
paradigm may be formulated to trigger thermosensitive ion channels endogenously expressed 
7 
 
in the peripheral nervous system (17), enabling wireless control in deep tissue regions that 
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Fig. 1. Wireless ON switch for controlled magnetothermal membrane depolarization of 
TRPV1
+
 cells. (A) Experimental scheme. Magnetic field stimulation (‘Field ON’) of TRPV1 
from MNP heating is visualized by gCaMP6s fluorescence changes. (B, C) Transmission 
electron micrographs of MNPs: (B) as-synthesized (C) and after surface modification with a 2 
nm poly(ethylene glycol) (PEG) shell. (D) Size distribution plot for poly(acrylic acid) (PAA) 
and PEG coated MNPs observed by dynamic light scattering. Aggregation in physiological 
fluids is observed for PAA coated MNPs but not for PEG coated MNPs. (E) Color maps of 




HEK293FT cells before and during 
magnetic field stimulus. Scale bar = 50 µm. (F) Normalized fluorescence intensity change 
(ΔF/F0) as a function  of  time  (solid  lines  =  mean,  shaded  grey  areas  =  standard  error).  
Dashed line corresponds to the crossing of TRPV1 activation threshold temperature. 
Fluorescence increase observed only in TRPV1
+ 
cells upon magnetic field application. Inset: 
Temperature profile without (gray) and with (red) magnetic field application. In all experiments 




Fig. 2. Alternating magnetic field stimulus evokes correlated and repeated trains of action 
potentials. (A) Confocal fluorescent images of co-transfected hippocampal neurons. Scale bar = 
25 µm. (B) Population study of 100 neurons from 3 trials counting the number of neurons that 
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spike within a 5 s bin following magnetic field stimulus. (C, D) Temperature profiles during 
magnetic field application in Tyrode’s solution without (C) and with (D) MNPs. Shaded area 
is the standard deviation with average value overlaid (black). (E-H) Example fluorescence 
traces of 10 individual neurons with average overlaid (black). (I-L) Raster plots of 100 
randomly selected neurons from 3 trials. Calcium spikes were counted according to an 
automated algorithm. (M-P) Peristimulus time histograms of the raster plots binned at 2 s. 
Color scheme for panels E-P: TRPV1
– 
neurons in Tyrode’s solution without MNPs (gray); 
TRPV1
– 
neurons in Tyrode’s solution with MNPs (red); TRPV1+ neurons in Tyrode’s solution 
without MNPs (blue); TRPV1
+ 
neurons in Tyrode’s with MNPs (orange). Shaded blue bars 





Fig. 3. Wireless magnetothermal stimulation in vivo. (A) In vivo experimental scheme. (B) 
Confocal image of a coronal slice representative of the TRPV1-p2A-mCherry expression profile 
in the VTA. (C-F) DAPI (cyan), mCherry (red), and c-fos (green) and overlay confocal images 
of regions used for quantification of neural stimulation. Scale bar = 25 µm. All animals were 
injected with MNPs.  Experimental conditions were (C) without (OFF) and (D) with (ON) 
magnetic field stimulation in TRPV1
– 
VTA, and (E) OFF and (F) ON stimulation in TRPV1
+
 
VTA. (G) Percentage of mCherry-positive and c-fos-positive neurons within cell population 
indicated by DAPI corresponding to the four conditions presented in C-F. Significance is 
confirmed by two-way ANOVA with Bonferroni post-hoc test (n=4, F1,13=47.5, P < 0.0001). 
(H, I) Confocal images of the VTA after acute magnetothermal stimulation. C-fos expression is 
largely confined to the VTA in regions where TRPV1 is expressed. Scale bar = 100 µm. (J-L) 
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Confocal images of the (J) VTA, (K) mPFC, and (L) NAc 1 month following MNP injection 
without (OFF) and with (ON) field treatment. Scale bar = 100 µm. (M) Percentage of c-fos+ 
neurons in the VTA among DAPI-labeled cells with and without magnetic field stimulation. 
Increased c-fos expression is observed following field treatment (ON) as compared to 
unstimulated (OFF) controls (n=3 OFF/ON; Student’s t-test, P < 0.02). (N, O) Similarly, 
upregulation is observed in (N) the mPFC and (O) in the NAc with alternating magnetic field 
(ON) as compared to the same regions without (OFF) the field stimulus (n=3 OFF/ON; Student’s 
t- test * P< 0.02, ** P < 0.002). 
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